Abstract
This review focuses on the roles of flow cytometric immunophenotyping has in the differential diagnosis of plasma cell neoplasms and the post-therapy monitoring of minimal (measurable) residual disease. The need to integrate flow cytometry data with clinical, laboratory, radiographic, morphological, and molecular genetic findings is emphasized. The challenges of and strategies for evaluating plasma cells in the setting of targeted therapy are also highlighted.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 338-350 |
| Number of pages | 13 |
| Journal | Cytometry Part B - Clinical Cytometry |
| Volume | 96 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 1 2019 |
Keywords
- flow cytometry
- immunophenotype
- minimal (measurable) residual disease
- plasma cell neoplasms
- targeted therapy
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Histology
- Cell Biology